Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Peritoneal Neoplasms 1Neoplasms, Glandular and Epithelial 1Ascites 1

Interventions

napabucasin 2Irinotecan 2Gemcitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sipuleucel-T 1pralsetinib 1pembrolizumab 1luprolide acetate gel depot 1catumaxomab 1Vaccines 1Papillomavirus Vaccines 1Papanicolaou Test 1Leuprolide 1Leucovorin 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Human Papillomavirus DNA Tests 1Fluorouracil 1Colposcopy 1Cisplatin 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Glandular and Epithelial × catumaxomab × Clear all
NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed
32 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡